阿托伐他汀对COPD急性加重期患者肺功能及诱导痰VEGF水平的影响

Effect of atorvastatin on pulmonary function and induced phlegm vascular endothelial growth factor in patients with acute exacerbation of chronic obstructive pulmonary disease

目的探讨阿托伐他汀对慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能及诱导痰血管内皮生长因子(VEGF)水平的影响。方法选择2016年8月至2017年10月期间东莞市石排医院收治的98例AECOPD患者为研究对象,根据随机数表法分为对照组和观察组,每组49例,对照组患者给予抗感染等常规治疗,观察组患者则同时联合阿托伐他汀治疗,疗程均为2周。比较两组患者治疗前后第一秒用力呼气量(FEV1)与用力肺活量(FVC)的比值(FEV1/FVC%),FEV1占预计值百分比(FEV1/预计值),以及诱导痰VEGF水平的变化。结果治疗后,观察组患者的治疗总有效率为91.84%,明显高于对照组的75.51%,差异有统计学意义(P<0.05);观察组患者的FEV1/预计值、FEV1/FVC及诱导痰VEGF水平分别为(53.44±9.12)%、(58.71±8.43)%和(811.6±254.5)pg/mL,明显高于对照组的(48.37±8.62)%、(52.95±7.26)%和(685.3±247.1)pg/mL,差异均有统计学意义(P<0.05)。结论阿托伐他汀应用于慢性阻塞性肺疾病急性加重期的治疗,可以提高患者的诱导痰VEGF水平,改善患者的肺功能,进而提高临床疗效。

Objective To investigate the effect of atorvastatin on pulmonary function and the level of vascular endothelial growth factor（VEGF） in induced sputum in patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods A total of 98 cases of patients with AECOPD treated in Shipai Hospital of Dongguan from August 2016 to October 2017 were selected as the subjects. According to the random number table method, these patients were divided into two groups, with 49 cases in each group. The control group was given conventional treatment, such as anti-infection, and the observation group was treated with conventional therapy combined with atorvastatin. The course of treatment was 2 weeks. The ratio of forced expiratory volume in 1 s to forced vital capacity（FEV1/FVC）, FEV1/predictive value and induced sputum VEGF level in the two groups were compared before and after the treatment. Results After the treatment, the effective rate of the observation group was 91.84%, which was significantly higher than 75.51% of the control group（P〈0.05）; the FEV1/predictive value, FEV1/FVC, induced sputum VEGF in the observation group were（53.44±9.12）%,（58.71±8.43）%,（811.6±254.5） pg/m L, respectively, which were significantly higher than corresponding（48.37±8.62）%,（52.95±7.26）%,（685.3±247.1） pg/m L in the control group（P〈0.05）.Conclusion The application of atorvastatin in the treatment of AECOPD can improve the induced sputum VEGF level,improve the lung function, and then improve the clinical efficacy.